+

WO1986000812A1 - A drug kit or drug composition for use in preventing and treating ischaemic cell damage and preparation thereof - Google Patents

A drug kit or drug composition for use in preventing and treating ischaemic cell damage and preparation thereof Download PDF

Info

Publication number
WO1986000812A1
WO1986000812A1 PCT/SE1985/000296 SE8500296W WO8600812A1 WO 1986000812 A1 WO1986000812 A1 WO 1986000812A1 SE 8500296 W SE8500296 W SE 8500296W WO 8600812 A1 WO8600812 A1 WO 8600812A1
Authority
WO
WIPO (PCT)
Prior art keywords
drug
composition according
kit
drug kit
radical scavenger
Prior art date
Application number
PCT/SE1985/000296
Other languages
French (fr)
Inventor
Karl-Erik Arfors
Bengt Gerdin
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of WO1986000812A1 publication Critical patent/WO1986000812A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients

Definitions

  • a drug kit or drug composition for use in preventing and treating ischaemic cell damage and preparation thereof ischaemic cell damage and preparation thereof.
  • the present invention relates to a drug kit or drug compositi for use in preventing and treating ischaemic cell damage.
  • the present invention is based on the concept that incurable tissue damage can be caused as a result of unfavourable con ⁇ ditions created when re-establishing the blood circulation to a body organ.
  • the transportation of calcium into and out of -a cell is of great significance.
  • the transportation of calcium into and out of a cell normally takes place while maintaining externally of the cell a calciu concentration which is 1000 times greater than the calcium concentration inside the cell.
  • a deficiency in energy occurs as a result of ischaemia, the calcium gradient cannot be maintained, and calcium will consequently leak into the cel Calcium is taken up in the cell by the mitochondria, resultin in serious disturbances in energy production.
  • blood agai starts to flow, calcium will enter the cell in still greater quantities, while transportation of calcium from the cell is impaired due to the fact that the build-up of energy in the cell is inhibited by the high calcium content thereof.
  • the drug kit or drug composition according to the invention is characterized in that it comprises a) at least one plasma volume expander; b) at least one low molecular, physiologically acceptable hydroxyl radical scavenger; c) at least one physiologically acceptable and water soluble magnesium salt; and d) at least one calcium blocking organic compound dissolved in a-carrier, either per. se or in one or more co binations.
  • the invention is described hereinafter with reference to a drug kit intended for single-unit administration, although the invention also relates to different stock solutions which might come into question.
  • the plasma volume expander used may be a physiologically acceptable high molecular substance known per se in the exp sion of blood plasma volume. These substances have an avera molecular weight M Vv (weight average value) which is higher than 10,000 Daltons, e.g. higher than 15,000 and preferably higher than 30,000 and lower than 400,000 and preferably lower than 300,000 Daltons. It is well known in the art that the average molecular weight K ⁇ chosen depends on the high molecular substance used. Examples of such plasma expanders are plasma-albumin and substances based on dextran, starch derivatives or gelatine derivatives. The dextran products normally have an average molecular weight M ⁇ within the rang of 30,000 to 80,000 Daltons.
  • starch derivatives for this purpose include hydroxyethyl starch having an avera molecular weight within the range of 40,000 - 400,000 Daltons, e.g. in the order of 200,000 Daltons.
  • hydroxyethyl starch having an avera molecular weight within the range of 40,000 - 400,000 Daltons, e.g. in the order of 200,000 Daltons.
  • gelatine derivatives of varying average molecular weights 1 ⁇ are also used for this purpose.
  • the concentration of plasma volume expander in the solution in which it is present is chosen so that subsequent to being optionally mixed with one or more solutions incorporated in the kit, the solution injected into the patient will have a plasma-volume-expander concentration which is normal in the use of the substance in question.
  • the plasma volume expa solution-of the .invention usually- has a concentration of 1-1 100 ml,.such as'2-12 g/100 ml, for example 3-10 g/100 ml.
  • hydroxyl radical scavengers whic ⁇ can be used in accordance with the invention is that they are physiologically acceptable and have a molecular weight beneath 10,000 Daltons, preferably beneath 1,000 Daltons. Hydroxyl radical scavengers which have a molecular weight above 10,000 Daltons as a rule have a poor effect. A suitabl hydroxyl radical scavenger is soluble in water at physio ⁇ logical pH and ion strengths.
  • hydroxyl radical scavenger is advantageously selected from the group comprising physio ⁇ logically acceptable sugar alcohols, monosaccharides, ol-Lgo- saccharides, amino acids which contain mercapto groups, and methionine and histidine.
  • mannitol is the primary choice, because it is able to function simultaneously as a diuretic and an anti-oedema agent.
  • Other sugar alcohols of interest in this context are sorbitol and xylitol.
  • physiologically acceptable monosaccha ⁇ rides are glucose and fructose, and of oligosaccharides malto oligosaccharides and isomalto-oligosaccharides (which can be obtained by means of partial hydrolysis of starch and dextran respectively), e.g. maltose.
  • Cysteine is an example of amino acids which contain mercapto groups.
  • the hydroxyl scavenger, used is preferably a combination of at least one sugar alcohol and at least one amino acid accord to the above, particularly a combination of mannitol and L-methionine, or of mannitol, L-methionine and histidine.
  • the ' concentration of hydroxyl radical scavenger is determined by the specific substance in question and by the amount it is desired to administer. It is always so high as to enable a therapeutically active quantity to be administered when the kit is used.
  • the drug kit or drug composition according to the invention may thus contain from 1 g up to 150 g hydrox radical scavenger.
  • the range of 1-10 g is particularly appli ⁇ cable in the case of methionine and histidine and a range of 5-150 g in the case of sugar alcohols, calculated per occasio of treatment.
  • Magnesium salt present in the composition comprises one or more salts from the group water-soluble, pharmaceutically acceptable magnesium salts.
  • magnesium salts which are thus comtemplated are magnesium sulphate and magnesium chloride. .Magnesium chloride is particularly preferred.
  • Wate soluble magnesium salts are present in the composition according to the invention in quantities corresponding to 5-100 m ol Mg 2+, calculted per occasion of treatment.
  • the organic compounds acting as calcium blockers are normally of low molecular weight, with a molecular weight beneath — 2000 Daltons. They are defined by their ability to prevent the migration of calcium ions into cells.
  • Cf. "Calcium Blockers" (edited by Flai , S.P. et al; Urban-and Scharzen- berg.
  • the compounds in question may be of highly different structure, niphedipine, nimodipine verapamil,. diltiazem, lidoflazine, flunarazine and analogous compounds can be mentioned by way of example.
  • the calcium blockers used in accordance with the invention may be soluble in water and/or in fat.
  • Verapamil(5- f(3,4-dimethoxyphenyleth methylaminoj -2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile is an example of a water-soluble calcium blocker
  • an example of a fat-soluble calcium blocker is lidoflazine(4- [4,4-bis(4-fluorophenyl)butyl] -N-(2,6-dimethylphenyl)-1-piper azine acetamide) .
  • a fat soluble calcium blocker is used in accordance with the invention, it is advantageously in ⁇ cluded in the kit as a component separate from the plasma volume expander. According to one aspect of the invention, this enables lidoflazine to be administered in a separate in ⁇ jection when using the drug kit.
  • the fat-soluble calcium blocker may be dissolved in, for example, :
  • the mixture can be acidified, to increase solubility. It is essential in this respect that acidification of the mixture is adapted to the pH and buffer capacity of the remaining kit components to be used on the occasion of the treatment.
  • the mixture is advantageously acidified with acetic, acid, hydrochloric acid, or some other physiologically acceptable acid.
  • the mixture may also contain glycerol.
  • a usable product in this connection is retailed under the name Intralipi ⁇ -'Dy Apoteksvarucentralen Vi'trum AB, Sweden.
  • This product contains fractionated soya oil in an • amount of 100 or 200 mg/ml, fractionated egg-phospholipides (as stabilizer) in an amount of 12 mg/ml, and glycerol in an amount of 25 mg/ml, with the remainder sterile water.
  • the amount of calcium blocker included in the kit varies from substance to substance. Calculated per occasion of treatment it is normally included in amounts of from 1 to 300 mg; a particular value for lidoflazine. is from 10 to 200 mg.
  • the carrier or vehicle in which the active kit components can be dissolved is physiologically acceptable and contains water. It may optionally be buffered with a physiologically acceptable buffer substance to a pH-value and an ion strength such that the total effect of that intended to be administer is physiologically acceptable.
  • a physiologically acceptable buffer substance to a pH-value and an ion strength such that the total effect of that intended to be administer is physiologically acceptable.
  • buffer systems include trometamol buffers, carbonate buffers, phosphate buffers, histidine buffers, acetate buffers and combinations thereof.
  • a buffer system may be included as a solutio separate from the solution containing the plasma volume expander, hydroxyl radical scavenger, magnesium salt.
  • a se ⁇ parate buffer system shall be used when acidose is present. It shall be capable of restoring the blood of the patient in question to a pH-value of from 7.0 to 8.0, preferably the physiological pH-value 7.4.
  • the buffer capacity lies in the region of 25-300 mmol, preferably 50-200 mmol. In practice this means that a separate buffer system shall have a pH-valu in the range of 7.0 - 10.0, preferably 7.4 - 9.2.
  • the drug kit or composition according to the invention pre ⁇ ferably also includes a diuretic agent, particularly an osmotic diuretic agent, and/or an anti-oedema substance.
  • a diuretic agent particularly an osmotic diuretic agent
  • an anti-oedema substance since in addition to being an hydroxyl radical scavenger, mannitol is also able to fulfil the function of both a diuretic and an anti-oedema substance, mannitol is a pre ⁇ ferred substance in the present context. Sorbitol or gly- cerol can be used-as a diuretic agent, either instead of or together with mannitol.
  • the quantities in which a diuretic agent and anti-oedema substance is used is dependent on the substance utilized, and may thus vary within wide limits. In the case of an osmotic diuretic agent, the quantities use may lie within the range 5-150 g, otherwise 0.1-200 mg. In the case of
  • an xanthine oxidase inhibitor such as allopurinol for example, (50 mg - 5 g, de pending on which is chosen)
  • a superoxide radical scavenger such as superoxide dismutase for example
  • an hydrogen peroxide inactivator such as catalase for exampl and/or a substance which binds iron in a solid complex, such as desferrioxamine or diethylenetriamine-pentaacetic acid or ethylenediamine-di(o-hydroxyphenylacetic acid), or a phyti acid derivative.
  • the active components included in the drug kit or drug compo sition are present in the form of a single solution or a plu rality of solutions. Precisely how they are combined is de ⁇ termined, inter alia, on the grounds of solubility and sta ⁇ bility, even though for practical reasons the aim is to plac them in a common solution.
  • the plasma volume expander, hydr - xyl radical scavenger, magnesium salt and calcium blocker are selected so as to be compatible with one another in solu- bilized form and with the desired pH-value of the solution to be administered.
  • the embod ment most preferred has a solution (A) which contains plasma volume expander, hydroxyl radical scavenger and magnesium sal a solution (B) which contains a buffer system and a solution or dispersion (C) which contains a fat-soluble calcium blocke
  • A which contains plasma volume expander, hydroxyl radical scavenger and magnesium sal
  • B which contains a buffer system
  • C solution or dispersion
  • the remaining active components are place in one of the solutions A, B or C.
  • allopurino is chosen as the xanthine-oxidase inhibitor, it can be added to the buffer solution B for reasons of solubility. If the kit does not include such a solution, it may be necessary to choose another xanthine-oxidase inhibitor.
  • the various solutions included in a drug kit according to the invention may have the form of sterile storage solutions from which a suitable quantity of the separate solutions or dispersion is taken on each treatment occasion; preferably, however, the kit is made up with dosages suited to the purpos each dosage containing therapeutically active quantities of the substances in question.
  • a solution (A) according to the aforegoing can be packed into units of
  • the unit ' s can -be poured into plastic sachets, glass or plastic bottles, ampoules, syringes etc.. The exact choice varies from case to case,.-and is determined, inter alia, by practical conside ⁇ rations. It can be mentioned by way of example that the solu ⁇ tion C is advantageously placed in an ampoule or disposable syringe .
  • the concentration in which the active components are present are selected so as to maintain the mutual proportions., be- tween the aforementioned quantities.
  • the concentration of hydroxyl radical scavenger and magnesium salt corresponds to the aforemen ⁇ tioned quantities per 500 ml of solution.
  • the calcium blocker when it is incorporated in the same solution as these, two substances.
  • the calcium blocker concentration may be from 10 to 100 times greater than in the previous case, due among other things to the solubility conditions.
  • the kit components When calculated on the basis of a patient weighing 70 kg, the kit components are normally administered to the patient in a total solution volume of 500-600 ml.
  • this unit When using a drug kit according to the invention in which the calcium blocker is included as a separate unit (C) , this unit is the first to be injected into the patient. It is de ⁇ sirable that this injection can be given relatively quickly.
  • ⁇ solution.- " (B.) is ' used to correct the pH of the patient.
  • the solution (B) may be mixed with the solution (A) immediately or shortly before being ' ' used.
  • the mixture, or the solutions (A) and (B) each per se, is or are then administered to the patient as soon as possib after having injected the patient with (C) . In the absence of metabolic acidose, only solution (A) is administered.
  • a drug composition according to the invention in which a plasma volume expander, an hydroxyl radical scavenge magnesium salt and a calcium blocker are present in a common solution separate from a buffer solution (B) , this common solution is injected into the patient separately or in mixtu with (B) .
  • the solution (B) is only used in the case of meta ⁇ bolic acidose.
  • the drug kit according to the invention is intended for use primarily in acute resuscitation, such as in the event of a cardiac arrest or in other situations in which blood circu-ta- tion collaps>es and the brain is subjected to ischaemia.
  • the drug kit can also be used in various kinds of trauma in the central nervous system, cerebral haemmorrhage, apoplectic str kes, subarachnoidal bleeding, or in the case of intracranial vessel surgery, where blood vessels must be temporarily close
  • the drug kit can also be used with ischaemic conditions in ot body organs, such as the heart, kidneys, intestines and skel ton muscle, in conjunction with shock, trauma, embolies and heart attacks, and also in surgical operations, such as heart surgery, vessel reconstruction and organ transplantation.
  • the drug kit can also be used as a perfusion solution and pr serving solution for body organs in, for example, cardioplegy or organ transplantation.
  • the invention also relates to a process for the preparation o a drug kit or drug composition which process is characterized by the features set forth in claim 11.
  • the invention also relates to a method of treating the afore ⁇ said conditions.
  • the components of the ki are administered in any of the ways described above.
  • lidoflazine 80 mg lidoflazine were dissolved in 1.0 g ethanol (99.5%), 0.1 g concentrated acetic acid and 1.5 g glycerol, and was 10. diluted up to 10 ml with distilled water. The solution was sterilized by sterile filtration and poured into a l ⁇ .ml ampoule' under aseptic conditions.
  • the tests were carried out with a rat model, which gives an 20 incomplete cerebral ischaemia with a cortical flow ⁇ 5% of the normal flow, and a flow in the brain stem which is about 30% of the normal flow. This is effected by squeezing the two carotid arteries while simultaneously lowering the blood pressure to 50 mm Hg, by bleeding.
  • the method has been de- 25 scribed by Nordstrom C.H. and Siesj ⁇ B.K., Stroke j), 327-335 (1978).
  • Wistar-rats weighing 300-400 g and fasted overnight were used in the tests.
  • the rats were anaesthetized with 4% Fluothane ⁇ 5
  • the EEG was recorded continuously during this time period, an the ischaemic period was taken to commence when an isoelec- tric EEG was obtained. Subsequent to an ischaemic period of 10 mins, the infusion of lidoflazine in the treatment group was commenced. Of a total dosage of 1.0 mg in one ml of a physiological sodium-jchloride solution, half was administere during the ischaemia and the remainder after 5 minutes re- circulation. A corresponding volume of physiological sodium chloride- solution was administered to a control group.
  • the mortality of the con ⁇ trol group was 60%.
  • the corresponding figure in the group treated with a drug kit according to the invention was 20%. No significant differences were observed with regard to average arterial blood pressure, blood gas or blood sugar. With regard to the pH of the blood, it was observed that the blood-pH of the animals in the group treated with a drug kit according to the invention fell after the ischaemic period to a lesser extent than that of the animals in the control group, this being attributed to the buffer capacity of the drug kit according to the invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Dentistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

A drug kit or drug composition for use in preventing and treating ischaemic cell damage comprises: a) at least one plasma volume expander; b) at least one low molecular, physiologically acceptable hydroxyl radical scavenger; c) at least one physiologically acceptable and water-soluble magnesium salt; and d) at least one organic compound active as a calcium blocking agent dissolved in a carrier, either per se or in one or several combinations.

Description

A drug kit or drug composition for use in preventing and treating ischaemic cell damage and preparation thereof.
The present invention relates to a drug kit or drug compositi for use in preventing and treating ischaemic cell damage.
When circulation of the blood collapses and ischaemia occurs in peripheral body organs, particularly in the brain, a large number of pathophysiological changes take place. In present clinical practice it is only possible to treat measurable pathophysiological- changes, for example changes in blood volume, impaired cardiac function, central acidosis, etc. In such cases each change has been treated individually and it can be said generally that present day therapy for the resuscitation of an organ is mainly directed towards re- establishing blood circulation.
The present invention is based on the concept that incurable tissue damage can be caused as a result of unfavourable con¬ ditions created when re-establishing the blood circulation to a body organ.
According to one aspect of th±s concept the transportation of calcium into and out of -a cell is of great significance. The transportation of calcium into and out of a cell normally takes place while maintaining externally of the cell a calciu concentration which is 1000 times greater than the calcium concentration inside the cell. When a deficiency in energy occurs as a result of ischaemia, the calcium gradient cannot be maintained, and calcium will consequently leak into the cel Calcium is taken up in the cell by the mitochondria, resultin in serious disturbances in energy production. When blood agai starts to flow, calcium will enter the cell in still greater quantities, while transportation of calcium from the cell is impaired due to the fact that the build-up of energy in the cell is inhibited by the high calcium content thereof. This greatly increases the load on the mitochondria, which can lead to incurable cell damage and cell death. According to another aspect of the concept there occurs dur the ischaemic period a gathering of degradation products, such as. hypoxanthine, which when oxygen is supplied in conn tion with the re-establishment of circulation are converted by certain enzymes, such as xanthine oxidase, in processes which produce free hydroxyl radicals as a secondary product, possibly via 02-radicals. Those enzyme systems which protec the tissue from the hydroxyl radicals are not able herewith to deal with the radicals at the rate in which they are for which can lead to. damage of blood vessels for example.
On the basis of these concepts concerning incurable tissue damage, there is now provided a drug kit or drug compositio which provides a better result and enables persons who are subjected to the risk of ischaemic cell damage to be treate in a simplified manner.
The drug kit or drug composition according to the invention is characterized in that it comprises a) at least one plasma volume expander; b) at least one low molecular, physiologically acceptable hydroxyl radical scavenger; c) at least one physiologically acceptable and water soluble magnesium salt; and d) at least one calcium blocking organic compound dissolved in a-carrier, either per. se or in one or more co binations.
The invention is described hereinafter with reference to a drug kit intended for single-unit administration, although the invention also relates to different stock solutions which might come into question.
The plasma volume expander used may be a physiologically acceptable high molecular substance known per se in the exp sion of blood plasma volume. These substances have an avera molecular weight M Vv (weight average value) which is higher than 10,000 Daltons, e.g. higher than 15,000 and preferably higher than 30,000 and lower than 400,000 and preferably lower than 300,000 Daltons. It is well known in the art that the average molecular weight K^ chosen depends on the high molecular substance used. Examples of such plasma expanders are plasma-albumin and substances based on dextran, starch derivatives or gelatine derivatives. The dextran products normally have an average molecular weight M^ within the rang of 30,000 to 80,000 Daltons. Examples of starch derivatives for this purpose include hydroxyethyl starch having an avera molecular weight
Figure imgf000005_0001
within the range of 40,000 - 400,000 Daltons, e.g. in the order of 200,000 Daltons. A number of different gelatine derivatives of varying average molecular weights 1^ are also used for this purpose. (A review of some plasma volume expanders is found, for example, in the book "Blood Replacement" by U.F. Gruber, Springer Verlag, Berlin- Heidelberg-New York.1969). Of these plasma volume expanders, those based on dextran are primarily preferred.
The concentration of plasma volume expander in the solution in which it is present is chosen so that subsequent to being optionally mixed with one or more solutions incorporated in the kit, the solution injected into the patient will have a plasma-volume-expander concentration which is normal in the use of the substance in question. The plasma volume expa solution-of the .invention usually- has a concentration of 1-1 100 ml,.such as'2-12 g/100 ml, for example 3-10 g/100 ml.
A common requirement of the hydroxyl radical scavengers whic ■ can be used in accordance with the invention is that they are physiologically acceptable and have a molecular weight beneath 10,000 Daltons, preferably beneath 1,000 Daltons. Hydroxyl radical scavengers which have a molecular weight above 10,000 Daltons as a rule have a poor effect. A suitabl hydroxyl radical scavenger is soluble in water at physio¬ logical pH and ion strengths. It normally includes a func- tional structure selected..from/aromatic or aliphatic thiol (-SH) , alcoholic and phenolic hydroxyl (-OH) and nitrogen- containing structures, such as primary amine (-NH2) secondar amine (-NH-) and imine (=NH) . The hydroxyl radical scavenger is advantageously selected from the group comprising physio¬ logically acceptable sugar alcohols, monosaccharides, ol-Lgo- saccharides, amino acids which contain mercapto groups, and methionine and histidine. Among the group of sugar alcohols, mannitol -is the primary choice, because it is able to functi simultaneously as a diuretic and an anti-oedema agent. Other sugar alcohols of interest in this context are sorbitol and xylitol. Examples of physiologically acceptable monosaccha¬ rides are glucose and fructose, and of oligosaccharides malto oligosaccharides and isomalto-oligosaccharides (which can be obtained by means of partial hydrolysis of starch and dextran respectively), e.g. maltose. Cysteine is an example of amino acids which contain mercapto groups.
The hydroxyl scavenger, used is preferably a combination of at least one sugar alcohol and at least one amino acid accord to the above, particularly a combination of mannitol and L-methionine, or of mannitol, L-methionine and histidine.
The'concentration of hydroxyl radical scavenger is determined by the specific substance in question and by the amount it is desired to administer. It is always so high as to enable a therapeutically active quantity to be administered when the kit is used. The drug kit or drug composition according to the invention may thus contain from 1 g up to 150 g hydrox radical scavenger. The range of 1-10 g is particularly appli¬ cable in the case of methionine and histidine and a range of 5-150 g in the case of sugar alcohols, calculated per occasio of treatment.
Magnesium salt present in the composition comprises one or more salts from the group water-soluble, pharmaceutically acceptable magnesium salts. Examples of magnesium salts which are thus comtemplated are magnesium sulphate and magnesium chloride. .Magnesium chloride is particularly preferred. Wate soluble magnesium salts are present in the composition according to the invention in quantities corresponding to 5-100 m ol Mg 2+, calculted per occasion of treatment. The organic compounds acting as calcium blockers are normally of low molecular weight, with a molecular weight beneath — 2000 Daltons. They are defined by their ability to prevent the migration of calcium ions into cells. Cf. "Calcium Blockers" (edited by Flai , S.P. et al; Urban-and Scharzen- berg. Baltimore-Munich, 1983). The compounds in question may be of highly different structure, niphedipine, nimodipine verapamil,. diltiazem, lidoflazine, flunarazine and analogous compounds can be mentioned by way of example. The calcium blockers used in accordance with the invention may be soluble in water and/or in fat. Verapamil(5- f(3,4-dimethoxyphenyleth methylaminoj -2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile is an example of a water-soluble calcium blocker, while an example of a fat-soluble calcium blocker is lidoflazine(4- [4,4-bis(4-fluorophenyl)butyl] -N-(2,6-dimethylphenyl)-1-piper azine acetamide) . When a fat soluble calcium blocker is used in accordance with the invention, it is advantageously in¬ cluded in the kit as a component separate from the plasma volume expander. According to one aspect of the invention, this enables lidoflazine to be administered in a separate in¬ jection when using the drug kit. In this variant of the in¬ vention, the fat-soluble calcium blocker may be dissolved in, for example, :
I. A mixture of water and ethanol in an amount which is physiologically acceptable for the purpose. When the calcium blocker has the nature of an amine, the mixture can be acidified, to increase solubility. It is essential in this respect that acidification of the mixture is adapted to the pH and buffer capacity of the remaining kit components to be used on the occasion of the treatment. The mixture is advantageously acidified with acetic, acid, hydrochloric acid, or some other physiologically acceptable acid. The mixture may also contain glycerol.
II. Physiologically acceptable fat emulsions used for paren- teral nutrition (a number of such emulsions are described, inter alia, in patent literature; cf.. for example the U.S. Patent Specification No. 4,168,308).
A usable product in this connection is retailed under the name Intralipiά-'Dy Apoteksvarucentralen Vi'trum AB, Stockholm, Sweden. This product contains fractionated soya oil in an • amount of 100 or 200 mg/ml, fractionated egg-phospholipides (as stabilizer) in an amount of 12 mg/ml, and glycerol in an amount of 25 mg/ml, with the remainder sterile water.
III. Physiologically acceptable emulsions of fluorinated hydrocarbons, which are administered parenterally due to their ability to dissolve and transport oxygen gas.
The amount of calcium blocker included in the kit varies from substance to substance. Calculated per occasion of treatment it is normally included in amounts of from 1 to 300 mg; a particular value for lidoflazine. is from 10 to 200 mg.
The carrier or vehicle in which the active kit components can be dissolved is physiologically acceptable and contains water. It may optionally be buffered with a physiologically acceptable buffer substance to a pH-value and an ion strength such that the total effect of that intended to be administer is physiologically acceptable. This means that in the selecti of a suitable buffer system, attention is paid to all compo¬ nents included in-the kit or the composition according to the invention. Examples of buffer systems include trometamol buffers, carbonate buffers, phosphate buffers, histidine buffers, acetate buffers and combinations thereof. According to the invention a buffer system may be included as a solutio separate from the solution containing the plasma volume expander, hydroxyl radical scavenger, magnesium salt. A se¬ parate buffer system shall be used when acidose is present. It shall be capable of restoring the blood of the patient in question to a pH-value of from 7.0 to 8.0, preferably the physiological pH-value 7.4. The buffer capacity lies in the region of 25-300 mmol, preferably 50-200 mmol. In practice this means that a separate buffer system shall have a pH-valu in the range of 7.0 - 10.0, preferably 7.4 - 9.2.
The drug kit or composition according to the invention pre¬ ferably also includes a diuretic agent, particularly an osmotic diuretic agent, and/or an anti-oedema substance. Since in addition to being an hydroxyl radical scavenger, mannitol is also able to fulfil the function of both a diuretic and an anti-oedema substance, mannitol is a pre¬ ferred substance in the present context. Sorbitol or gly- cerol can be used-as a diuretic agent, either instead of or together with mannitol. The quantities in which a diuretic agent and anti-oedema substance is used is dependent on the substance utilized, and may thus vary within wide limits. In the case of an osmotic diuretic agent, the quantities use may lie within the range 5-150 g, otherwise 0.1-200 mg. In the case of the anti-oedema substance a corresponding range may be 5-150 g.
It may also be of advantage to incorporate in the kit or the composition according to the invention an xanthine oxidase inhibitor, such as allopurinol for example, (50 mg - 5 g, de pending on which is chosen) , and/or a superoxide radical scavenger, such as superoxide dismutase for example, and/or an hydrogen peroxide inactivator, such as catalase for exampl and/or a substance which binds iron in a solid complex, such as desferrioxamine or diethylenetriamine-pentaacetic acid or ethylenediamine-di(o-hydroxyphenylacetic acid), or a phyti acid derivative.
The quantities quoted above in respect of the diuretic agent, anti-oedema substance and xanthine-oxidase inhibitor apply to each occasion of treatment.
The active components included in the drug kit or drug compo sition are present in the form of a single solution or a plu rality of solutions. Precisely how they are combined is de¬ termined, inter alia, on the grounds of solubility and sta¬ bility, even though for practical reasons the aim is to plac them in a common solution. For example, in accordance with one advantageous variant, the plasma volume expander, hydr - xyl radical scavenger, magnesium salt and calcium blocker are selected so as to be compatible with one another in solu- bilized form and with the desired pH-value of the solution to be administered. Similar considerations are applicable to remaining active components such as the a tiroedema substance, diuretic agent, xanthine-oxidase inhibitor, superoxide radi¬ cal scavenger, hydrogen peroxide inactivator and iron-binding substance.
On the basis of those studies carried out hitherto, the embod ment most preferred has a solution (A) which contains plasma volume expander, hydroxyl radical scavenger and magnesium sal a solution (B) which contains a buffer system and a solution or dispersion (C) which contains a fat-soluble calcium blocke In this embodiment, the remaining active components are place in one of the solutions A, B or C. For example, if allopurino is chosen as the xanthine-oxidase inhibitor, it can be added to the buffer solution B for reasons of solubility. If the kit does not include such a solution, it may be necessary to choose another xanthine-oxidase inhibitor.
The various solutions included in a drug kit according to the invention (and in certain cases the dispersion of organic cal cium blocker) may have the form of sterile storage solutions from which a suitable quantity of the separate solutions or dispersion is taken on each treatment occasion; preferably, however, the kit is made up with dosages suited to the purpos each dosage containing therapeutically active quantities of the substances in question. In this latter case a solution (A) according to the aforegoing can be packed into units of
100-1000 ml, normally 500 ml, a solution (B) packed in units of 10-100 preferably 25-100 ml,- and a- solution or dispersion (C)- packed in" units of 5-50" "ml," preferably 10-30 ml." The unit's can -be poured into plastic sachets, glass or plastic bottles, ampoules, syringes etc.. The exact choice varies from case to case,.-and is determined, inter alia, by practical conside¬ rations. It can be mentioned by way of example that the solu¬ tion C is advantageously placed in an ampoule or disposable syringe .
The concentration in which the active components are present are selected so as to maintain the mutual proportions., be- tween the aforementioned quantities. In the aforesaid pre¬ ferred embodiments, the concentration of hydroxyl radical scavenger and magnesium salt corresponds to the aforemen¬ tioned quantities per 500 ml of solution. The same applies to the calcium blocker, when it is incorporated in the same solution as these, two substances. When it is present in a se parate solution (C) , the calcium blocker concentration may be from 10 to 100 times greater than in the previous case, due among other things to the solubility conditions.
When calculated on the basis of a patient weighing 70 kg, the kit components are normally administered to the patient in a total solution volume of 500-600 ml.
When using a drug kit according to the invention in which the calcium blocker is included as a separate unit (C) , this unit is the first to be injected into the patient. It is de¬ sirable that this injection can be given relatively quickly. In those cases where metabolic acidose prevails, as with a cardiac arrest for example, ■solution.-"(B.) is' used to correct the pH of the patient. The solution (B) may be mixed with the solution (A) immediately or shortly before being' ' used. The mixture, or the solutions (A) and (B) each per se, is or are then administered to the patient as soon as possib after having injected the patient with (C) . In the absence of metabolic acidose, only solution (A) is administered.
When using a drug composition according to the invention in which a plasma volume expander, an hydroxyl radical scavenge magnesium salt and a calcium blocker are present in a common solution separate from a buffer solution (B) , this common solution is injected into the patient separately or in mixtu with (B) . The solution (B) is only used in the case of meta¬ bolic acidose. The drug kit according to the invention is intended for use primarily in acute resuscitation, such as in the event of a cardiac arrest or in other situations in which blood circu-ta- tion collaps>es and the brain is subjected to ischaemia. The drug kit can also be used in various kinds of trauma in the central nervous system, cerebral haemmorrhage, apoplectic str kes, subarachnoidal bleeding, or in the case of intracranial vessel surgery, where blood vessels must be temporarily close The drug kit can also be used with ischaemic conditions in ot body organs, such as the heart, kidneys, intestines and skel ton muscle, in conjunction with shock, trauma, embolies and heart attacks, and also in surgical operations, such as heart surgery, vessel reconstruction and organ transplantation.
The drug kit can also be used as a perfusion solution and pr serving solution for body organs in, for example, cardioplegy or organ transplantation.
The invention also relates to a process for the preparation o a drug kit or drug composition which process is characterized by the features set forth in claim 11.
The invention also relates to a method of treating the afore¬ said conditions. In such a treatment the components of the ki are administered in any of the ways described above.
The invention will now be described with reference to a numbe of working examples.
EXAMPLE 1
Preparation of a drug kit
Solution A
15 g dextran having an average molecular weight (R^) of about 60 000, 4.0 g MgCl2 (anhydrous), 25 g mannitol, 5 g L-methio- nine, and 5 g L-histidine were dissolved in 500 ml distilled water. The resultant solution was sterilized by sterile fil¬ tration and poured into a 500 ml sterile plastics bag, which was then sealed under aseptic conditions. Solution B
There were used for this solution 50 ml of a conventional^ commercial buffer solution having a pH of 9.2 and containing 20 g trometamol with a buffer capacity of 150 mmol (Addex-' 5 THAM form Pharmacia Infusion AB, Uppsala, Sweden) .
Solution C
80 mg lidoflazine were dissolved in 1.0 g ethanol (99.5%), 0.1 g concentrated acetic acid and 1.5 g glycerol, and was 10. diluted up to 10 ml with distilled water. The solution was sterilized by sterile filtration and poured into a l} .ml ampoule' under aseptic conditions.
The solutions A, B and C were then packed in a box, as a unit
15
EXAMPLE 2 Pharmacological tests
The tests were carried out with a rat model, which gives an 20 incomplete cerebral ischaemia with a cortical flow < 5% of the normal flow, and a flow in the brain stem which is about 30% of the normal flow. This is effected by squeezing the two carotid arteries while simultaneously lowering the blood pressure to 50 mm Hg, by bleeding. The method has been de- 25 scribed by Nordstrom C.H. and Siesjδ B.K., Stroke j), 327-335 (1978).
Wistar-rats weighing 300-400 g and fasted overnight were used in the tests. The rats were anaesthetized with 4% Fluothane^5
30 (ICI-Pharma AB, Gothenburg, Sweden) , 30% 02/70% 20, intubate and connected to a respirator. The vena jugularis externa was uncovered. Celocurine (5 mg/kg) was injected and a cathe¬ ter was placed in vena cava superior. Catheters were also placed in the tail artery and in a tail vein for measuring
35 blood pressure and infusion, respectively. EEG-electrodes were applied and finally 5 ml 0.9% NaCl were administered int peritoneally and 100 IU heparin . intravenously. The supply of Fluothane ^ was cut-off, whereafter blood gases, pH and the sugar content of the blood were measured for a period of at least 30 minutes. It was endeavoured to obtain a pH in th_g region of 7.35 - 7.40, pC02 of 4.67 - 5.50 kPa, and p02 o_ξ 11.0 - 18.0 kPa, and a bloodsugar content in the region 3.0 - 8.0 mmol/1. If these criteria were not attained, the animal was excluded.
The following procedure was undertaken in order to create ischaemia:
A solution of trimethaphan-D-camghQrsulphσnate. in sterile wate (15 mg/ml, Arfonad ® from Hoffmann-La Roche & Co AG, Basle, Switzerland) was administered intravenously, until the average blood pressure was 80 mm Hg, whereafter the two caro arteries of respective animals were shut-off and blood was drained from the animals through respective catheters in vena cava superior until an average blood pressure of 50 mm was reached.
The EEG was recorded continuously during this time period, an the ischaemic period was taken to commence when an isoelec- tric EEG was obtained. Subsequent to an ischaemic period of 10 mins, the infusion of lidoflazine in the treatment group was commenced. Of a total dosage of 1.0 mg in one ml of a physiological sodium-jchloride solution, half was administere during the ischaemia and the remainder after 5 minutes re- circulation. A corresponding volume of physiological sodium chloride- solution was administered to a control group. Infusion of an aqueous solution containing 3.5% albumin, 10% mannitol, .2% L-methionine, 92.2 mM; magnesium chloride and 0.5 M Tris (percentages given in w/v) , was commenced during the last two minutes of the ischaemic perio and was continued for two minutes" during the recirculation phase. A total of 2 ml were injected. The blood pressure was monitored during the infusion period and adjusted when necessary, by bleeding the animal or infusing blood there¬ into. The rats were left in the respirator until they began to waken, whereupon they were ventilated for two minutes with 100% oxygen gas and the respirator then disconnected. Tracheal tubes and oxygen masks were left in position until stable breathing was observed.
Of 10 test animals in each group, the mortality of the con¬ trol group was 60%. The corresponding figure in the group treated with a drug kit according to the invention was 20%. No significant differences were observed with regard to average arterial blood pressure, blood gas or blood sugar. With regard to the pH of the blood, it was observed that the blood-pH of the animals in the group treated with a drug kit according to the invention fell after the ischaemic period to a lesser extent than that of the animals in the control group, this being attributed to the buffer capacity of the drug kit according to the invention.

Claims

C L A I M S
1. A drug kit or drug composition for use in preventing- > and treating ischaemic cell damage, characterized in that
5 it contains: a) at least one plasma volume expander; b) at least one low molecular, physiologically •acceptable hydroxyl radical scavenger; c) at least one physiologically acceptable and water- 10 soluble magnesium salt; and d) at least one organic compound active as a calcium blocking agent dissolved in a carrier, either per se or in one or several combinations.
15
2. A drug kit or composition according to Claim 1, charac¬ terized in that the plasma volume expander is plasma-albumin or is based on dextran, a starch derivative or gelatin deri¬ vative.
20
3. A drug kit or composition according to Claim 1 or Claim characterized in that the hydroxyl radical scavenger comprise one or more substances from the group physiologically accept¬ able sugar alcohols, monosaccharides, oligosaccharides, amino
25 acids which contain mercapto groups, methionine and histidine
4. A drug kit or composition according to any one of Claims 1-3, characterized in that the magnesium salt is magnesium sulphate or magnesium chloride.
30
5. A drug kit or composition according to any one of Claims 1-4, characterized in that the calcium blocker is lidoflazine
6. A drug kit or composition according to any one of Claims 35 1-5, characterized in that it also includes a diuretic agent and/or anti-oedema substance.
7. A drug kit or composition according to Claim 6, charac¬ terized in that the diuretic agent is mannitol and/or sorbit
8. A drug kit or composition according to Claim 6, charac¬ terized in that the anti-oedema substance is mannitol. -»
9. A drug kit or composition according, to. any one of Claims 1-8, characterized in that it also includes an xanthine oxidase inhibitor and/or a superoxide radical scavenger and/or a hydrogen peroxide inactivator and/or an iron- binding substance.
10. A drug kit or composition according to.any one of Claim 1-9, characterized in that it also includes a physiological acceptable buffer system.
11. Process for the preparation of a drug kit or drug compo sition for use in preventing and treating ischaemic cell damage, characterized by dissolving a) at least one plasma volume expander; b) at least one law molecular, physiologically acceptabl hydroxal radical scavenger; σ) at least one physiologically acceptable and water- soluble magnesium salt; and d) at least one organic compound active as a calcium blocking agent in a carrier, either per se or in one or several combination
PCT/SE1985/000296 1984-07-30 1985-07-30 A drug kit or drug composition for use in preventing and treating ischaemic cell damage and preparation thereof WO1986000812A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8403912-2 1984-07-30
SE8403912A SE8403912D0 (en) 1984-07-30 1984-07-30 PHARMACEUTICAL KIT OR COMPOSITION

Publications (1)

Publication Number Publication Date
WO1986000812A1 true WO1986000812A1 (en) 1986-02-13

Family

ID=20356627

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1985/000296 WO1986000812A1 (en) 1984-07-30 1985-07-30 A drug kit or drug composition for use in preventing and treating ischaemic cell damage and preparation thereof

Country Status (6)

Country Link
EP (1) EP0188595A1 (en)
JP (1) JPS61502821A (en)
AU (1) AU4671385A (en)
CA (1) CA1246449A (en)
SE (1) SE8403912D0 (en)
WO (1) WO1986000812A1 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939146A (en) * 1987-01-29 1990-07-03 Kramer Richard S Method for alleviating ischemic-reperfusion injury
EP0356367A3 (en) * 1988-08-16 1991-04-17 José Maria Grino Boira Liquid medium for infusion and preservation of organs
WO1994008612A1 (en) * 1992-10-22 1994-04-28 Thomas Peter G New method of protecting central nervous system against damage resulting from cerebrovascular or neuronal compromise
ES2050580A1 (en) * 1990-11-20 1994-05-16 Pasteur Merieux Serums Vacc Solutions for the perfusion, preservation and reperfusion of organs
WO1997025044A1 (en) * 1996-01-11 1997-07-17 Peter Buhl Jensen Topoisomerase ii poison and bis-dioxypiperazine derivative combination therapy
WO1999002034A1 (en) * 1997-07-09 1999-01-21 Wayne State University Flush-storage solution for donor organs
WO2000019817A1 (en) * 1998-10-07 2000-04-13 Cedars-Sinai Medical Center Cell preconditioning and cryopreservation medium
WO2000018226A3 (en) * 1998-09-29 2000-05-25 Life Science Holdings Inc Apparatus and method for maintaining and/or restoring viability of organs
WO2000067743A1 (en) * 1999-05-10 2000-11-16 Nikken Chemicals Co., Ltd. Radical scavenger
US6265385B1 (en) 1996-01-11 2001-07-24 Topo Target Aps Topoisomerase II poison and bis-dioxopiperazine derivative combination therapy
WO2001054495A1 (en) * 2000-01-31 2001-08-02 Organ Recovery Systems, Inc. System for organ and tissue preservation and hypothermic blood substitution
WO2007105179A1 (en) * 2006-03-15 2007-09-20 Universitat Bern Cardioplegic solution
US20110183010A1 (en) * 2008-08-22 2011-07-28 Erich Gygax Cardioplegic preparation
US8962303B2 (en) 1998-09-29 2015-02-24 Lifeline Scientific, Inc. Apparatus and method for maintaining and/or restoring viability of organs

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0012272A1 (en) * 1978-12-14 1980-06-25 Dr. Franz Köhler Chemie KG Protecting solution for heart and kidneys and process for its manufacture
CH624579A5 (en) * 1975-07-18 1981-08-14 Behringwerke Ag
EP0054635A1 (en) * 1980-12-23 1982-06-30 Dr. Franz Köhler Chemie GmbH Protective solution for heart and kidney, and manufacturing process
EP0085033A1 (en) * 1982-01-18 1983-08-03 Pharmacia Ab A pharmaceutical composition
US4407801A (en) * 1980-09-30 1983-10-04 Science Union Et Cie Anti-ischemic pharmaceutic compositions
WO1984003623A1 (en) * 1983-03-24 1984-09-27 Maurice Bloch Pharmaceutical compositions

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH624579A5 (en) * 1975-07-18 1981-08-14 Behringwerke Ag
EP0012272A1 (en) * 1978-12-14 1980-06-25 Dr. Franz Köhler Chemie KG Protecting solution for heart and kidneys and process for its manufacture
US4407801A (en) * 1980-09-30 1983-10-04 Science Union Et Cie Anti-ischemic pharmaceutic compositions
EP0054635A1 (en) * 1980-12-23 1982-06-30 Dr. Franz Köhler Chemie GmbH Protective solution for heart and kidney, and manufacturing process
EP0085033A1 (en) * 1982-01-18 1983-08-03 Pharmacia Ab A pharmaceutical composition
WO1984003623A1 (en) * 1983-03-24 1984-09-27 Maurice Bloch Pharmaceutical compositions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts, Vol 92 (1980), abstract No 15670s, Surg. Forum 1979, 30, 435-7 (Eng.) *
E Schroder et al, "Pharmazeutische Chemie", published 1982, by Georg Thieme Verlag (Stuttgart), see pages 660-661 *
Federation Proceedings, Vol. 40, No 14, issued December 1981 (Washington) S F Flaim & R Zelis "Clinical use of calcium entry blockers", see pages 2877-2881, especially page 2877 (abstract) and page 2880, the second column ("Lidoflazine") *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939146A (en) * 1987-01-29 1990-07-03 Kramer Richard S Method for alleviating ischemic-reperfusion injury
EP0356367A3 (en) * 1988-08-16 1991-04-17 José Maria Grino Boira Liquid medium for infusion and preservation of organs
ES2050580A1 (en) * 1990-11-20 1994-05-16 Pasteur Merieux Serums Vacc Solutions for the perfusion, preservation and reperfusion of organs
WO1994008612A1 (en) * 1992-10-22 1994-04-28 Thomas Peter G New method of protecting central nervous system against damage resulting from cerebrovascular or neuronal compromise
US6265385B1 (en) 1996-01-11 2001-07-24 Topo Target Aps Topoisomerase II poison and bis-dioxopiperazine derivative combination therapy
WO1997025044A1 (en) * 1996-01-11 1997-07-17 Peter Buhl Jensen Topoisomerase ii poison and bis-dioxypiperazine derivative combination therapy
WO1999002034A1 (en) * 1997-07-09 1999-01-21 Wayne State University Flush-storage solution for donor organs
US8962303B2 (en) 1998-09-29 2015-02-24 Lifeline Scientific, Inc. Apparatus and method for maintaining and/or restoring viability of organs
WO2000018226A3 (en) * 1998-09-29 2000-05-25 Life Science Holdings Inc Apparatus and method for maintaining and/or restoring viability of organs
US6485959B1 (en) 1998-10-07 2002-11-26 Cedars Sinai Medical Center Cell preconditioning and cryopresevation medium
WO2000019817A1 (en) * 1998-10-07 2000-04-13 Cedars-Sinai Medical Center Cell preconditioning and cryopreservation medium
JP2001026536A (en) * 1999-05-10 2001-01-30 Nikken Kasei Kk Radical scavenger
WO2000067743A1 (en) * 1999-05-10 2000-11-16 Nikken Chemicals Co., Ltd. Radical scavenger
WO2001054495A1 (en) * 2000-01-31 2001-08-02 Organ Recovery Systems, Inc. System for organ and tissue preservation and hypothermic blood substitution
US6492103B1 (en) 2000-01-31 2002-12-10 Organ Recovery Systems, Inc. System for organ and tissue preservation and hypothermic blood substitution
US6994954B2 (en) 2000-01-31 2006-02-07 Organ Recovery Systems, Inc. System for organ and tissue preservation and hypothermic blood substitution
WO2007105179A1 (en) * 2006-03-15 2007-09-20 Universitat Bern Cardioplegic solution
US20110183010A1 (en) * 2008-08-22 2011-07-28 Erich Gygax Cardioplegic preparation
US9763979B2 (en) * 2008-08-22 2017-09-19 Universitat Bern Cardioplegic preparation

Also Published As

Publication number Publication date
SE8403912D0 (en) 1984-07-30
CA1246449A (en) 1988-12-13
JPS61502821A (en) 1986-12-04
EP0188595A1 (en) 1986-07-30
AU4671385A (en) 1986-02-25

Similar Documents

Publication Publication Date Title
Mark et al. The physiological disposition and cardiac effects of procaine amide
Allen et al. Neuropeptide Y (NPY) reduces myocardial perfusion and inhibits the force of contraction of the isolated perfused rabbit heart
WO1986000812A1 (en) A drug kit or drug composition for use in preventing and treating ischaemic cell damage and preparation thereof
US4657532A (en) Intra-peritoneal perfusion of oxygenated fluorocarbon
KR101119334B1 (en) Bicarbonate-Based Solutions for Dialysis Therapies
Turner-Lawrence et al. Intravenous fat emulsion: a potential novel antidote
JPH09500380A (en) Solution for tissue preservation and bloodless surgery, and method using the same
US4609372A (en) Heat sterilizable storage solution for red blood cells
JP2009131669A (en) Bicarbonate-based solution in single container
JPS63502107A (en) Solution to stabilize red blood cells during storage
Levine et al. Perioperative recombinant human erythropoietin
Cassin et al. The effects of bumetanide and furosemide on lung liquid secretion in fetal sheep
Yang et al. Haemoperfusion treatment in pigs experimentally intoxicated by paraquat
Laurant et al. Dietary magnesium supplementation modifies blood pressure and cardiovascular function in mineralocorticoid-salt hypertensive rats but not in normotensive rats
Ames et al. Effect of infusions of citrated plasma on the plasma citrate level of infants
Case et al. Intra-Arterial and Intravenous Blood Infusion in Hemorrhagic Shock: Comparison of Effects on Coronary Blood Flow and Arterial Pressure
Acar et al. Studies of controlled reperfusion after ischemia: XIX. Reperfusate composition: Benefits of blood cardioplegia over Fluosol DA cardioplegia during regional reperfusion—Importance of including blood components in the initial reperfusate
US7270833B2 (en) Cardioplegic solution
US8753806B2 (en) Organ protection solution and method of use
SU1395251A1 (en) Method of preserving dead body
EP0059057A1 (en) Treatment of diarrhoea
RU2815501C1 (en) Solution for pre-transplant preparation of donor lungs
Littledike et al. Oxalate (Halogeton) poisoning of sheep: certain physiopathologic changes.
US11185574B2 (en) Protective solution for preventing or reducing reperfusion injury of the brain and the whole body
MOORE et al. A method for the control of severe alterations in acid-base equilibrium

Legal Events

Date Code Title Description
AK Designated states

Designated state(s): AU DK FI JP NO US

AL Designated countries for regional patents

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1985903893

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1985903893

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1985903893

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载